Positive Media Coverage Somewhat Unlikely to Impact Avadel Pharmaceuticals (AVDL) Share Price

News stories about Avadel Pharmaceuticals (NASDAQ:AVDL) have trended positive on Friday, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Avadel Pharmaceuticals earned a news sentiment score of 0.30 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 47.2917824534947 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the media headlines that may have impacted Accern Sentiment Analysis’s analysis:

Avadel Pharmaceuticals opened at $6.98 on Friday, according to Marketbeat Ratings. Avadel Pharmaceuticals has a 12 month low of $6.90 and a 12 month high of $7.18. The company has a current ratio of 2.66, a quick ratio of 2.59 and a debt-to-equity ratio of 1.28.

Avadel Pharmaceuticals (NASDAQ:AVDL) last released its earnings results on Wednesday, May 2nd. The company reported ($0.32) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.08). Avadel Pharmaceuticals had a negative return on equity of 13.95% and a net margin of 18.96%. The company had revenue of $33.29 million for the quarter, compared to analyst estimates of $29.60 million. equities analysts expect that Avadel Pharmaceuticals will post -1.55 EPS for the current fiscal year.

Avadel Pharmaceuticals declared that its board has approved a stock buyback program on Tuesday, March 27th that authorizes the company to buyback $7.00 million in shares. This buyback authorization authorizes the company to repurchase up to 2.7% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Several research firms recently issued reports on AVDL. BidaskClub upgraded Avadel Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, January 23rd. Zacks Investment Research downgraded Avadel Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 16th. ValuEngine downgraded Avadel Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, March 9th. Ladenburg Thalmann cut their price objective on Avadel Pharmaceuticals to $24.00 and set a “buy” rating on the stock in a report on Friday, March 9th. Finally, TheStreet downgraded Avadel Pharmaceuticals from a “c” rating to a “d+” rating in a report on Thursday, March 8th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $20.00.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc develops and commercializes pharmaceutical products primarily for treating urology and sleep medicines in the United States, France, and Ireland. Its commercial products that are used in the hospital setting include Bloxiverz, a drug used in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; Vazculep, a phenylephrine hydrochloride injection that is used for the treatment of hypotension occurring in the setting of anesthesia; and Akovaz, an ephedrine sulfate injection for treating hypotension, as well as Noctiva for treating nocturia due to nocturnal polyuria.

Insider Buying and Selling by Quarter for Avadel Pharmaceuticals (NASDAQ:AVDL)

Receive News & Ratings for Avadel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply